Overview

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004)

Status:
Not yet recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 randomized part to assess JCAR017 monotherapy treatment versus standard of care. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of JCAR017 will be evaluated.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Juno Therapeutics, Inc.